Company Overview - Neo Performance Materials Inc. is a manufacturer of advanced industrial materials that enhance efficiency and sustainability, including magnetic powders, rare earth magnets, and specialty chemicals [5] - The company operates in three segments: Magnequench, Chemicals & Oxides, and Rare Metals, with a global presence including manufacturing facilities in China, Germany, Canada, Estonia, Thailand, and the UK, as well as a dedicated R&D center in Singapore [5] Market Transition - Neo Performance Materials has upgraded to trade on the OTCQX Best Market from the Pink market, which is a significant step for enhancing transparency and accessibility for U.S. investors [1][3] - The company will begin trading under the symbol "NOPMF" on the OTCQX, allowing U.S. investors to access real-time financial disclosures [2] Strategic Positioning - The CEO of Neo Performance Materials emphasized that the upgrade to OTCQX enhances the company's visibility and accessibility for U.S. investors, positioning it well to meet the growing demand for critical materials in electrification and modern technologies [4] - The company aims to broaden its shareholder base while executing its strategic priorities to drive long-term value [4]

Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].

Core Insights - HydroGraph Clean Power Inc. has appointed two new independent directors, Tom Wilkinson and Grant Duthie, to strengthen its board as the company transitions to commercial operations [1][2][3] Group 1: Board Appointments - The new directors bring extensive experience in operations, strategy, leadership, audit, governance, and public company management, aligning with the company's focus on innovation and growth [2][3] - The appointments fill vacancies left by the resignations of Paul Cox and David Williams, who left to pursue other business interests [5] Group 2: Company Transition - HydroGraph is moving from a development stage to commercial operations, with a growing pipeline of prospective customers for its graphene products across various end markets [3][4] - The company aims to secure its first commercial customers and build a scalable high-volume manufacturing facility to establish itself as a global leader in the graphene industry [4] Group 3: New Directors' Background - Tom Wilkinson has over thirty years of experience as a business leader and advisor, previously serving as CFO for Amelia Holdings and CEO for multiple technology companies [6][7] - Grant Duthie is a partner at Garfinkle & Biderman, focusing on securities, corporate finance, and M&A, with experience in advising various industry sectors [9][10]

TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Fury Gold Mines Limited (TSX and NYSE American: FURY) ("Fury" or the "Company") announces that the proposed private placement offering announced June 5, 2025 has been increased from C$2,500,000 to C$3,080,000. Fury now intends to privately place with a small group of accredited and institutional investors in Canada a total of 4,000,000 flow-through common shares (the "Shares") of the Company, at a price of C$0.77 per Share for total gross proceeds of C$3,080,000 (t ...

VANCOUVER, BC, June 06, 2025 (GLOBE NEWSWIRE) -- Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) ("Eat & Beyond" or the "Company"), is pleased to announce that that globally recognized entrepreneur, investor, and citizen journalist Mario Nawfal has joined the Company as a Strategic Advisor. Mr. Nawfal is a force in modern media and Web3 innovation. As the founder of The Roundtable, X/Twitter's most influential audio show, he has hosted global icons including Elon Musk, Marc Andreesse ...

U.S. Indication and Important Safety Information INDICATION ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands ...

Senior Analyst Max Ma presented "Navigating China's Market Pulse in 2025: Data-Driven Strategic Investment Insights," offering global investment institutions and enterprise clients an in-depth analysis of the latest trends in China's macroeconomy and key industry sectors. As global investors increasingly focus on the Chinese market, data-driven market insights have become a critical foundation for institutional decision-making and corporate strategic planning. Against the backdrop of a complex, evolving mac ...

NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results fro ...

Core Insights - ABM reported a return to organic revenue growth in its Business & Industry segment, achieving 3.8% organic revenue growth and a total revenue increase of 4.6% to $2.1 billion for the second quarter of fiscal 2025 [2][4][7] - The company secured $1.1 billion in new bookings, marking an 11% year-over-year increase, indicating strong market positioning and innovation focus [2][4] - Adjusted net income rose to $54.1 million, or $0.86 per diluted share, compared to $52.3 million, or $0.82 per diluted share, in the prior year [6][7] Financial Performance - Revenue for the second quarter increased to $2.1 billion, driven by 3.8% organic growth and a 0.8% contribution from acquisitions [4][7] - Net income for the quarter was $42.2 million, or $0.67 per diluted share, down from $43.8 million, or $0.69 per diluted share, in the prior year [5][7] - Adjusted EBITDA for the period increased to $125.9 million, maintaining an adjusted EBITDA margin of 6.2% [8][7] Segment Performance - The Business & Industry segment grew by 3%, supported by recovery in the U.S. prime office space market [4][28] - The Manufacturing & Distribution segment saw a 2% increase, attributed to new client wins and favorable comparisons to the prior year [4][28] - Technical Solutions and Aviation segments reported significant revenue increases of 19% and 9%, respectively, with Technical Solutions benefiting from higher microgrid revenue [4][28] Cash Flow and Liquidity - Net cash provided by operating activities was $32.3 million, a decrease from $117.0 million in the prior year, primarily due to elevated working capital related to the ERP transition [9][23] - Free cash flow for the quarter was $15.2 million, down from $101.4 million in the previous year [9][32] - The company had total indebtedness of $1.6 billion and available liquidity of $657.8 million at the end of the second quarter [10][9] Outlook - ABM reaffirmed its fiscal year 2025 adjusted EPS outlook in the range of $3.65 to $3.80, with an unchanged projected adjusted EBITDA margin of 6.3% to 6.5% [12][7] - The company remains optimistic about core markets, particularly high-quality office buildings, manufacturing and distribution facilities, and commercial aviation [2][12]

LIBERTY, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- Ferrellgas Partners, L.P. (OTC: FGPR) (“Ferrellgas” or the “Company”) today reported financial results for its 2025 third fiscal quarter ended April 30, 2025. Tamria Zertuche, President and Chief Executive Officer, commented, “We are very pleased to have delivered strong third quarter sales growth of 9%, which translated into solid gross profit, and net earnings growth of 12%. This growth was driven by our strong field performance in inclement weather and resi ...